Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.
Döhner
Hartmut
H
Department of Internal Medicine III, University of Ulm, Ulm, Germany. hartmut.doehner@uniklinik-ulm.de
Estey
Elihu H
EH
Amadori
Sergio
S
Appelbaum
Frederick R
FR
Büchner
Thomas
T
Burnett
Alan K
AK
Dombret
Hervé
H
Fenaux
Pierre
P
Grimwade
David
D
Larson
Richard A
RA
Lo-Coco
Francesco
F
Naoe
Tomoki
T
Niederwieser
Dietger
D
Ossenkoppele
Gert J
GJ
Sanz
Miguel A
MA
Sierra
Jorge
J
Tallman
Martin S
MS
Löwenberg
Bob
B
Bloomfield
Clara D
CD
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D006287:Health Planning Guidelines; D006801:Humans; D007391:International Cooperation; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D055815:Young Adult